Vaginal Nystatin Versus Oral Fluconazole for the Treatment for Recurrent Vulvovaginal Candidiasis

Mycopathologia

Volumn 179, Issue 1-2, 2015, Pages 95-101

  Fan, Shangrong ^a,b   Liu, Xiaoping ^a   Wu, Cong ^a   Xu, Lixuan ^a   Li, Jianling ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research   (China)

Author keywords

Antifungal susceptibility; Candida; Fluconazole; Nystatin; Recurrent vulvovaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; NYSTATIN;

ADOLESCENT; ADULT; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME; VAGINA; VULVA; YOUNG ADULT;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; NYSTATIN; RECURRENCE; TREATMENT OUTCOME; VAGINA; VULVA; YOUNG ADULT;

EID: 84925500815     PISSN: 0301486X     EISSN: 15730832     Source Type: Journal    
DOI: 10.1007/s11046-014-9827-4     Document Type: Article

References (21)

1. Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340–5.
2. Sobel JD. Genital candidiasis. Medicine. 2010;38:286–90.
3. Aballéa S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel J, Toumi M. Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.
4. Workowski KA, Berman S. Centers for disease control and prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1–110.
5. Mendling W, Brasch J. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55(Suppl 3):1–13.
6. Colombo AL, Guimarães T, Camargo LF, Richtmann R, de Queiroz-Telles F, Salles MJ, Cunha CA, Yasuda MA, Moretti ML, Nucci M. Brazilian guidelines for the management of candidiasis: a joint meeting report of three medical societies: Sociedadebrasileira de Infectologia, Sociedade Paulista de Infectologia and SociedadeBrasileira de Medicina Tropical. Braz J Infect Dis. 2013;17:283–312.
7. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C 3rd, Horowitz B, Von Thron J, Edwards L, Panzer H, Chu TC. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876–83.
8. Donders G, Bellen G, Byttebier G. Individualised decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199:613.e1–9.
9. Rosa MI, Silva BR, Pires PS, Silva FR, Silva NC, Silva FR, Souza SL, Madeira K, Panatto AP, Medeiros LR. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167:132–6.
10. Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol. 2007;47(4):262–72.
11. Rosco Diagnostica A/S. User’s guide for neo-sensitabs susceptibility testing. 19th ed. Taastrup, Denmark: Rosco Diagnostica A/S; 2007/2008.
12. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253–73.
13. Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in southern China from 2003 to 2012. J Mycol Med. 2014;24(2):106–11.
14. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43:2155–62.
15. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis. 2009;64:354–6.
16. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.
17. Fan SR, Liu XP. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses. 2011;54:501–5.
18. Fan SR, Liu XP, Li JW. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res. 2008;34:561–6.
19. Witt A, Kaufmann U, Bitschnau M, Tempfer C, Ozbal A, Haytouglu E, Gregor H, Kiss H. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG. 2009;116:1499–505.
20. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189:1297–300.
21. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203.